Home > Publications . Search All . Browse All . Country . Browse PSC Pubs . PSC Report Series

PSC In The News

RSS Feed icon

Edin and Shaefer's book a call to action for Americans to deal with poverty

Weir says pain may underlie rise in suicide and substance-related deaths among white middle-aged Americans

Weitzman says China's one-child policy has had devastating effects on first-born daughters


MCubed opens for new round of seed funding, November 4-18

PSC News, fall 2015 now available

Barbara Anderson appointed chair of Census Scientific Advisory Committee

John Knodel honored by Thailand's Chulalongkorn University

Next Brown Bag

Monday, Dec 7 at noon, 6050 ISR-Thompson
Daniel Eisenberg, "Healthy Minds Network: Mental Health among College-Age Populations"

Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification

Archived Abstract of Former PSC Researcher

Schmittdiel, J.A., C.S. Uratsu, A.J. Karter, Michele Heisler, U. Subramanian, C.M. Mangione, and J.V. Selby. 2008. "Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification." Journal of General Internal Medicine, 23(5): 588-594.

BACKGROUND: Despite the availability of effective hypertension, hyperlipidemia, and hyperglycemia therapies, target levels of systolic blood pressure (SBP), LDL-cholesterol (LDL-c), and hemoglobin A1c control are often not achieved. OBJECTIVE: To examine the relative importance of patient medication nonadherence versus clinician lack of therapy intensification in explaining above target cardiovascular disease (CVD) risk factor levels. DESIGN: Cross-sectional assessment. PARTICIPANTS: In 2005, 161,697 Kaiser Permanente Northern California adult diabetes patients were included in the study. MEASUREMENT: "Above target" was defined as most recent A1c >= 7.0% for hyperglycemia, LDL-c >= 100 mg/dL for hyperlipidemia, and SBP >= 130 mmHg for hypertension. Poor adherence was defined as medication gaps for >= 20% of days covered for all medications for each condition separately. Treatment intensification was defined as an increase in the number of drug classes, increased dosage of a class, or a switch to a different class within the 3 months before or after notation of above target levels. RESULTS: Poor adherence was found in 20-23% of patients across the 3 conditions. No evidence of poor adherence with no treatment intensification was found in 30% of hyperglycemia patients, 47% of hyperlipidemia patients, and 36% of hypertension patients. Poor adherence or lack of therapy intensification was evident in 53-68% of patients above target levels across conditions. CONCLUSIONS: Both nonadherence and lack of treatment intensification occur frequently in patients above target for CVD risk factor levels; however, lack of therapy intensification was somewhat more common. Quality improvement efforts should focus on these modifiable barriers to CVD risk factor control.

DOI:10.1007/s11606-008-0554-8 (Full Text)

PMCID: PMC2324158. (Pub Med Central)

Browse | Search : All Pubs | Next